Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well gemcitabine, cisplatin, nab-paclitaxel and durvalumab
work before surgery in treating participants with Biliary Tract Cancer. The international
multicenter phase III clinical study TOPAZ-1 has confirmed that durvalumab combined with
gemcitabine and cisplatin can bring survival benefits to advanced BTC. Drugs used in
chemotherapy, such as nab-paclitaxel, cisplatin, and gemcitabine, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Giving combination chemotherapy and Durvalumab before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital